- Home
- AGIO vs GDYN Comparison
AGIO vs GDYN Comparison
Compare AGIO & GDYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- GDYN
- Stock Information
- Founded
- AGIO 2007
- GDYN 2006
- Country
- AGIO United States
- GDYN United States
- Employees
- AGIO N/A
- GDYN N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- GDYN Computer Software: Prepackaged Software
- Sector
- AGIO Health Care
- GDYN Technology
- Exchange
- AGIO Nasdaq
- GDYN Nasdaq
- Market Cap
- AGIO 1.4B
- GDYN 1.2B
- IPO Year
- AGIO 2013
- GDYN N/A
- Fundamental
- Price
- AGIO $32.09
- GDYN $12.53
- Analyst Decision
- AGIO Buy
- GDYN Strong Buy
- Analyst Count
- AGIO 8
- GDYN 4
- Target Price
- AGIO $56.00
- GDYN $18.75
- AVG Volume (30 Days)
- AGIO 550.4K
- GDYN 681.4K
- Earning Date
- AGIO 05-01-2025
- GDYN 05-01-2025
- Dividend Yield
- AGIO N/A
- GDYN N/A
- EPS Growth
- AGIO N/A
- GDYN 322.00
- EPS
- AGIO 11.45
- GDYN 0.13
- Revenue
- AGIO $37,035,000.00
- GDYN $371,169,000.00
- Revenue This Year
- AGIO $27.43
- GDYN $21.68
- Revenue Next Year
- AGIO $189.81
- GDYN $15.70
- P/E Ratio
- AGIO $2.80
- GDYN $99.48
- Revenue Growth
- AGIO 25.96
- GDYN 18.72
- 52 Week Low
- AGIO $23.42
- GDYN $9.07
- 52 Week High
- AGIO $62.58
- GDYN $25.50
- Technical
- Relative Strength Index (RSI)
- AGIO 65.51
- GDYN 35.69
- Support Level
- AGIO $29.05
- GDYN $12.72
- Resistance Level
- AGIO $30.45
- GDYN $13.26
- Average True Range (ATR)
- AGIO 1.13
- GDYN 0.50
- MACD
- AGIO 0.33
- GDYN -0.11
- Stochastic Oscillator
- AGIO 91.98
- GDYN 1.76
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.